Share on LinkedInShare on LinkedIn

ARTICLE · 16 MAY 2007

Connecticut Attorney General Investigating Possible Anticompetitive Impact of Practice Guidelines

Medical societies and associations of health professionals routinely adopt and disseminate practice guidelines, opine in position papers, provide expertise, and engage in advocacy before policymakers and, increasingly, before third-party payors on issues of concern to their membership. While these activities are generally designed to promote the highest quality patient care, they often, too, are in the best interest, sometimes the best pecuniary interest, of their members, and sometimes also hav

United StatesAntitrust/Competition Law

Medical societies and associations of health professionals routinely adopt and disseminate practice guidelines, opine in position papers, provide expertise, and engage in advocacy before policymakers and, increasingly, before third-party payors on issues of concern to their membership. While these activities are generally designed to promote the highest quality patient care, they often, too, are in the best interest, sometimes the best pecuniary interest, of their members, and sometimes also have the effect of excluding certain products and services from the market.

The recent announcement by Richard Blumenthal, Connecticut’s Attorney General, of an investigation into the potentially anticompetitive impact of practice guidelines for the treatment of Lyme Disease—issued this past fall by the Infectious Diseases Society of America ("IDSA" or "Society")—has some in the scientific community crying "foul." At a minimum, however, Mr. Blumenthal’s investigation should serve as a caution to

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from